Related Experiment Videos
Cost-effective treatment of coronary artery disease--the new imperative
1Lawrence Berkeley Laboratory, University of California, Berkeley, USA.
Insights
Lipid-lowering therapies significantly reduce cardiovascular events, potentially saving over $1,500 per patient annually. Applying these treatments broadly to coronary artery disease patients could yield national savings exceeding one billion dollars yearly.
Area of Science:
- Cardiovascular Medicine
- Health Economics
Background:
- Large-scale clinical trials show lipid-lowering treatments reduce cardiovascular events and procedures.
- Current treatment modalities vary in intensity and cost-effectiveness.
Purpose of the Study:
- To evaluate the cost-effectiveness of lipid-lowering therapies in managing cardiovascular disease.
- To estimate potential healthcare cost savings associated with widespread adoption of effective lipid-lowering strategies.
Main Methods:
- Analysis of data from large lipid-lowering clinical trials and arteriographic studies.
- Economic modeling balancing treatment costs against savings from reduced cardiovascular events.
Main Results:
- Clinical trials indicated an average net saving of approximately $1,500 per patient per year.
- Arteriographic studies showed a wide range of cost implications, from savings of $901 to costs of $2,273 per patient annually.
- Extrapolation to the US coronary artery disease population suggests potential annual savings over $1 billion.
Conclusions:
- Lipid-lowering therapies are cost-effective in reducing cardiovascular events.
- Widespread implementation of effective lipoprotein management strategies could lead to substantial national healthcare cost savings for coronary artery disease patients.
Abstract:
Large lipid-lowering clinical trials have demonstrated a significant reduction in cardiovascular events and the need for cardiovascular procedures. These clinical and point trials used relatively weak treatment modalities, and when the cost savings of the reduced number of events is balanced against the estimated cost of treatment, the average difference is approximately $1,500 per patient per year. Arteriographic trials have used similar or more aggressive lipoprotein therapy over shorter periods of time. Estimates of cost savings from reduced clinical events balanced against the cost of treatment in these studies indicate a wide spectrum of estimated patient costs. These estimates range between a cost of $2,273 per patient per year to a cost savings of (-)$901 per patient per year. Extrapolation to the United States population with coronary artery disease (CAD) suggests that greater than one billion dollars per year could be saved if patients with CAD received similar treatment and responded in a similar manner.